Viral particle with surface stimulating molecules
AssigneeUmoja Biopharma, Inc.
InventorsChristopher NICOLAI, Jim QIN, Wai-hang LEUNG, Ryan LARSON, Alyssa SHEIH, Byoung RYU
Life of this patent
Estimating the term…
Abstract
Provided are viral particles for activating and transducing immune cells in vitro or in vivo, and compositions and methods for using said viral particles.
Claims83
A viral particle, comprising a viral envelope comprising on the surface of the viral envelope at least one T-cell adhesion molecule, at least one co-stimulatory protein, or combination thereof, and an immune cell-activating protein.
A viral particle comprising (i) a viral envelope comprising on the surface of the viral envelope (a) an immune cell-activating protein, wherein the immune cell-activating protein binds a T cell receptor, (b) a co-stimulatory molecule, and (c) a T cell adhesion molecule, and (ii) a vector genome comprising at least one nucleotide sequence encoding a polypeptide of interest.
A viral particle comprising (i) a viral envelope comprising on the surface of the viral envelope (a) an immune cell-activating protein that specifically binds CD3, (b) a co-stimulatory molecule, wherein the co-stimulatory molecule binds CD28, and (c) a T cell adhesion molecule, and (ii) a vector genome comprising (a) a nucleotide sequence encoding a rapamycin-activated cell-surface receptor, and (b) a nucleotide sequence encoding a CAR, wherein the CAR comprises an antigen binding domain specific for a cancer-associated antigen, optionally wherein the nucleotide sequences are operably linked.
The viral particle of any one of 4-10, 12, 14, 15-19, 21-45, 47-48, wherein CD86 comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:
- 23.
Dependencies are inferred from the claim text.